Trial Profile
A Window Study to Assess the Activity of Demethylation Therapy in Patients With HPV-Positive Compared With HPV-Negative Head and Neck Squamous Cell Carcinoma, With Response Assessment and Biomarker Expansion Cohort in HPV-Positive Oropharynx Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Feb 2022
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary)
- Indications Head and neck cancer; Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 31 Jan 2022 Status changed from recruiting to completed.
- 18 Dec 2020 Planned End Date changed from 1 May 2021 to 1 Nov 2021.
- 18 Dec 2020 Planned primary completion date changed from 1 Nov 2020 to 1 Nov 2021.